Spark Investment Management LLC purchased a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 4th quarter, HoldingsChannel reports. The fund purchased 270,900 shares of the biopharmaceutical company’s stock, valued at approximately $3,898,000.
A number of other institutional investors also recently made changes to their positions in FOLD. Strs Ohio acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $102,000. Birchview Capital LP acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $151,000. Sage Capital Advisors llc acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $154,000. Engineers Gate Manager LP acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $155,000. Finally, Neuberger Berman Group LLC acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $196,000.
In other Amicus Therapeutics news, insider Jay Barth sold 5,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $13.59, for a total value of $67,950.00. Following the completion of the sale, the insider now owns 69,184 shares of the company’s stock, valued at $940,210.56. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Bradley L. Campbell sold 32,500 shares of the firm’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $15.92, for a total value of $517,400.00. Following the completion of the sale, the chief operating officer now directly owns 186,600 shares of the company’s stock, valued at approximately $2,970,672. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 250,390 shares of company stock valued at $3,620,581. Corporate insiders own 3.40% of the company’s stock.
Several equities research analysts have recently weighed in on FOLD shares. Zacks Investment Research downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th. Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 7th. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, January 15th. Leerink Swann increased their price objective on Amicus Therapeutics from $20.00 to $24.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Finally, Cowen reaffirmed a “buy” rating and set a $22.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. Amicus Therapeutics has a consensus rating of “Buy” and a consensus target price of $19.06.
WARNING: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3228717/spark-investment-management-llc-takes-position-in-amicus-therapeutics-inc-fold.html.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.